Literature DB >> 31966547

MicroRNA-30b targets CBX3 and regulates cell proliferation, apoptosis, and migration in esophageal squamous cell carcinoma via the JAK2/STAT3 signaling pathway.

Lingxin Meng1, Fengsong Wang1, Shuyan Sun2, Yuxiu Zheng1, Zhaojun Ding1, Yanwei Sun1, Bingcheng Li1, Qin Meng1, Meiling Xu1.   

Abstract

The present study aimed to investigate whether miR-30b plays a pivotal role in the progression of esophageal squamous cell carcinoma (ESCC) as well as to elucidate its possible regulatory mechanism. The expression levels of miR-30b in the ESCC tissues and cells were determined. The TE-1 cells were transfected with the miR-30b mimic, the mimic control, the miR-30b inhibitor, the inhibitor control, the pCDNA3.1-Chromobox 3 (pCDNA3.1-CBX3) and/or the blank vector, while the TE-2 cells were transfected with the miR-30b mimic and/or the mimic control. Cell proliferation, cell apoptosis, and cell migration of the different transfected groups were evaluated. The luciferase reporter assay was performed to detect the relationship between miR-30b, and CBX3. Furthermore, the relationship between miR-30b, CBX3, and the JAK2/STAT3 signaling pathway was explored. Significant downregulation of miR-30b was observed in the ESCC tissues and cells, while CBX3 was upregulated in the ESCC tissues and cells. The inhibition of miR-30b promoted cell proliferation, inhibited cell apoptosis, and enhanced cell migration in ESCC, which was similar to the effects of CBX3 overexpression. In fact, CBX3 was confirmed to be a direct target of miR-30b. The overexpression of miR-30b decreased the expression levels of p-JAK2/JAK2 and p-STAT3/JAK3 significantly, which was obviously reversed after the simultaneous overexpression of CBX3. Our results revealed that the downregulation of miR-30b may increase cell proliferation, inhibit cell apoptosis, and promote cell migration in ESCC by targeting CBX3 and activating the JAK2/STAT3 signaling pathway. Thus, miR-30b may serve as a useful marker for predicting the progression of ESCC. IJCEP
Copyright © 2017.

Entities:  

Keywords:  Chromobox 3; Esophageal squamous cell carcinoma; JAK2/STAT3 pathway; miR-30b

Year:  2017        PMID: 31966547      PMCID: PMC6966038     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  6 in total

1.  CBX3 Regulated By YBX1 Promotes Smoking-induced Pancreatic Cancer Progression via Inhibiting SMURF2 Expression.

Authors:  Huan Zhang; Haixin Yu; Dianyuan Ren; Yan Sun; Feng Guo; Hongkun Cai; Chen Zhou; Yingke Zhou; Xin Jin; Heshui Wu
Journal:  Int J Biol Sci       Date:  2022-05-13       Impact factor: 10.750

2.  Clinicopathological and Prognostic Significance of CBX3 Expression in Human Cancer: a Systematic Review and Meta-analysis.

Authors:  Hexin Lin; Xin Zhao; Lu Xia; Jiabian Lian; Jun You
Journal:  Dis Markers       Date:  2020-11-12       Impact factor: 3.434

3.  A novel prognostic mRNA/miRNA signature for esophageal cancer and its immune landscape in cancer progression.

Authors:  Yue Zhao; Li Xu; Xinyu Wang; Shuai Niu; Hezhong Chen; ChunGuang Li
Journal:  Mol Oncol       Date:  2021-02-08       Impact factor: 6.603

4.  Molecular mechanism, regulation, and therapeutic targeting of the STAT3 signaling pathway in esophageal cancer (Review).

Authors:  Rui-Jie Ma; Chao Ma; Kang Hu; Meng-Meng Zhao; Nan Zhang; Zhi-Gang Sun
Journal:  Int J Oncol       Date:  2022-07-20       Impact factor: 5.884

5.  Systematic investigation of the clinical significance and prognostic value of the CBXs in esophageal cancer.

Authors:  Jun Hou; Yinfeng Yang; Honglei Gao; Ting Ouyang; Qiwei Liu; Ran Ding; Hongxing Kan
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

6.  Therapeutic siRNAs Targeting the JAK/STAT Signalling Pathway in Inflammatory Bowel Diseases.

Authors:  Flora Clément; Adrien Nougarède; Stéphanie Combe; Frédérique Kermarrec; Arindam K Dey; Patricia Obeid; Arnaud Millet; Fabrice P Navarro; Patrice N Marche; Eric Sulpice; Xavier Gidrol
Journal:  J Crohns Colitis       Date:  2022-02-23       Impact factor: 9.071

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.